Decrease in antioxidant status of plasma and erythrocytes from patients with ankylosing spondylitis

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 566-570

  Stanek, Agata ^a   CieŚlar, Grzegorz ^a   Romuk, Ewa ^a   Kasperczyk, SŁawomir ^a   Sieroń Stołtny, Karolina ^a   Birkner, Ewa ^a   Sieroń, Aleksander ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Ankylosing spondylitis; Inflammatory markers; Oxidant antioxidant balance; Oxidative stress; Reactive oxygen species

Indexed keywords

CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; SUPEROXIDE DISMUTASE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CHEMICAL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ERYTHROCYTE; HUMAN; MALE; OXIDATIVE STRESS; PATHOGENESIS; PLASMA; PRIORITY JOURNAL; TOTAL ANTIOXIDANT STATUS;

ADULT; ANTIOXIDANTS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CATALASE; DOWN-REGULATION; ERYTHROCYTES; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; MUCOPROTEINS; PLASMA; SPONDYLITIS, ANKYLOSING; SUPEROXIDE DISMUTASE;

EID: 77950862504     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.019     Document Type: Article

References (57)

1. Albu A., Parasca I., Talu S., Poanta L. Ankylosing spondylitis - a systemic disease. Rom. J. Intern. Med. 2004, 42:685-694.
2. Gause A., Schnabel A. Rheumatology 2003 - Part I: Research news concerning pathogenesis, epidemiology, diagnosis, and therapy of chronic inflammatory joint diseases. Med. Klin. 2003, 98:523-533. 2003.
3. Kataria R.K., Brent L.H. Spondyloarthropathies. Am. Fam. Physician 2004, 69:2853-2860.
4. Landewe R.B., van Tubergen A. Clinical assessment and outcome research in spondyloarthritis. Curr. Rheumatol. Rep. 2009, 11:334-339.
5. Karakoc M., Altindag O., Keles H., Soran N., Selek S. Serum oxidative-antioxidative status in patients with ankylosing spondilitis. Rheumatol. Int. 2007, 27:1131-1134.
6. Khan M.A., Ball E.J. Genetic aspects of ankylosing spondylitis. Best Pract. Res. Clin. Rheumatol. 2002, 16:675-679.
7. Kim T.H., Uhm W.S., Inman R.D. Pathogenesis of ankylosing spondylitis and reactive arthritis. Curr. Opin. Rheumatol. 2005, 17:400-405.
8. Marker-Hermann E., Frauendorf E., Zeidler H., Sieper J. Pathogenesis of ankylosing spondylitis - mechanisms of disease manifestation and chronicity. Z. Rheumatol. 2004, 63:187-192.
9. Ozgocmen S., Sogut S., Ardicoglu O., Fadillioglu E., Pekkutucu I., Akyol O. Serum nitric oxide, catalase, superoxide dismutase, and malondialdehyde status in patients with ankylosing spondylitis. Rheumatol. Int. 2004, 24:80-83.
10. Lakomek H.J., Plomman M., Specker C., Schwechau M. Ankylosing spondylitis: an autoimmune disease?. Ann. Rheum. Dis. 1991, 50:776-781.
11. Pham T. Pathopysiology of ankylosing spondylitis: what's new?. Joint Bone Spine 2008, 75:656-660.
12. Reveille J.D. Recent studies on the genetic basis of ankylosing spondylitis. Curr. Rheumatol. Rep. 2009, 11:340-345.
13. Woodrow J.C., Eastmond C.J. HLA B27 and the genetics of ankylosing spondylitis. Ann. Rheum. Dis. 1978, 37:504-509.
14. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
15. Halliwell B. Oxidants and human disease: some new concepts. FASEB J. 1987, 1:358-364.
16. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
17. Van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis a proposal for modification of the New York Criteria. Arthritis Rheum. 1984, 27:361-368.
18. Braun J., Golder W., Bollow M., Sieper J., Van der Heude D. Imaging and scoring in ankylosing spondylitis. Clin. Exp. Rheumatol. 2002, 20(Suppl. 28):178.
19. Garrett S., Jenkinson T., Kennedy L.G., Whitelock H., Gaisford P., Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J. Rheumatol. 1994, 21:2286-2291.
20. Oyanagui Y. Reevaluation of assay methods and establishment of kit for superoxide dismutase activity. Anal. Biochem. 1984, 142:290-296.
21. Aebi H. Catalase in vitro. Methods Enzymol. 1984, 105:121-126.
22. Paglia D.E., Valentine W.N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J. Lab. Clin. Med. 1967, 70:158-169.
23. Richterich R. Clinical chemistry: theory and practice 1969, Academic Press, New York.
24. Habig W.H., Jakoby W.B. Assays for differentiation of glutathione S-transferases. Methods Enzymol. 1981, 77:398-405.
25. Ohkawa H., Ohisi N., Yagi K. Assay for peroxides in animal tissue by thiobarbituric acid reaction. Annal. Biochem. 1979, 95:351-358.
26. Downton S.B., Colton H.R. Acute phase reactants in inflammation and infection. Semin. Hematol. 1988, 25:84-90.
27. De La Huerga J., Dubin A., Kushner D.S., Dyniewicz H.A., Popper H. Studies of serum mucoprotein (seromucoid). I. A turbidimetric method. J. Lab. Clin. Med. 1956, 47:403-408.
28. Thomas L. Clinical and laboratory diagnostics 1998, TH Books Verlags GmbH, Frankfurt/Main. 5th ed.
29. Abramson S.B., Amin A.R., Clancy R.M., Attur M. The role of nitric oxide in tissue destruction. Best Pract. Res. Clin. Rheumatol. 2001, 15:831-845.
30. Bauerová K., Bezek A. Role of reactive oxygen and nitrogen species in etiopathogenesis of rheumatoid arthritis. Gen. Physiol. Biophys. 1999, 18:15-20.
31. Cimen M.Y., Cimen O.B., Kacmaz M., Ozturk H.S., Yorgancioglu R., Durak I. Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin. Rheumatol. 2000, 19:275-277.
32. Gelderman K.A., Hultqvist M., Olsson L.M., et al. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxid. Redox. Signal 2007, 9:1541-1567.
33. Hadjigogos K. The role of free radicals in the pathogenesis of rheumatoid arthritis. Panminerva Med. 2003, 45:7-13.
34. Mazzetti I., Grigolo B., Pulsatelli L., et al. Differential roles of nitric oxide and oxygen radicals in chondrocytes affected by osteoarthritis and rheumatoid arthritis. Clin. Sci. (Lond). 2001, 101:593-599.
35. Nakamura K., Endo H., Kashiwazaki S. Serum oxidation activities and rheumatoid arthritis. Int. J. Tissue React. 1987, 9:307-316.
36. Chang C.H., Fang H.W., Ho Y.C., Huang H.T. Chondrocyte acting as phagocyte to internalize polyethylene wear particles and leads to the elevations of osteoarthritis associated NO and PGE2. Biochem. Biophys. Res. Commun. 2008, 369:884-888.
37. Greenwald R.A., Moy W. Effect of oxygen-derived free radicals on hyaluronic acid. Arthritis Rheum. 1980, 23:455-463.
38. Henrotin Y.E., Bruckner P., Pujol J.P. The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 2003, 11:747-755.
39. Kowanko I.C., Bates E.J., Ferrante A. Platelet-activating factor inhibits proteoglycan synthesis and enhances neutrophil-mediated proteoglycan degradation in cartilage explants. Arthritis Rheum. 1992, 35:918-925.
40. Schiller J., Benard S., Reichl S., Arnhold J., Arnold K. Cartilage degradation by stimulated human neutrophils: reactive oxygen species decrease markedly the activity of proteolytic enzymes. Chem. Biol. 2000, 7:557-568.
41. Altindag O., Karakoc M., Kocyigit A., Celik H., Soran N. Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin. Biochem. 2007, 40:167-171.
42. Bashir S., Harris G., Denman M.A., Blake D.R., Winyard P.G. Oxidative DNA damage and cellular sensitivity to oxidative stress in human autoimmune diseases. Ann. Rheum. Dis. 1993, 52:659-666.
43. Dargel R. Lipid peroxidation a common pathogenetic mechanism?. Exp. Toxicol. Pathol. 1992, 44:169-181.
44. Naskalski J.W., Bartosz G. Oxidative modifications of protein structures. Adv. Clin. Chem. 2000, 35:161-253.
45. Mitrofanova O.V., Bagirova V.V., Krasikov S.I. Levels of lipid peroxidation products and activity of antiradical defense enzymes in blood of patients with Bechterew disease. Ter. Arkh. 2002, 74:66-69.
46. Halliwell B. Antioxidants in human health and disease. Annu. Rev. Nutr. 1996, 16:33-50.
47. Halliwell B. Antioxidants: the basics - what they are and how to evaluate them. Adv. Pharmacol. 1997, 38:3-20.
48. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic. Res. 1999, 31:261-272.
49. Griffiths H.R., Moller L., Bartosz G., et al. Biomarkers. Mol. Aspects Med. 2002, 23:101-208.
50. Collins A.R. Assays for oxidative stress and antioxidant status: applications to research into the biological effectiveness of polyphenols. Am. J. Clin. Nutr. 2005, 81(suppl 1):261S-267S.
51. Bartosz G. Total antioxidant capacity. Adv. Clin. Chem. 2003, 37:219-292.
52. Ghisell A., Serafini M., Natella F., Scaccini C. Total antioxidant capacity as a tool to assess redox status: critical view and experimental data. Free Radic. Biol. Med. 2000, 29:1106-1114.
53. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:6858-6862.
54. Benzie I.F.F., Strain J.J. Uric acid: friend or foe. Redox. Report 1996, 2:231-234.
55. Chan A.C. Partners in defense. Vitamin E and vitamin C. Can J. Physiol. Pharmacol. 1993, 7:725-731.
56. Liu B., Guo C.Y., Liu W.Q., Wu N., Xing Q. The value of erythrocyte sedimentation rate and C-reactive protein in evaluating disease activity in ankylosing spondylitis. Zhonghua Nei Ke Za Zhi 2005, 44:566-569.
57. Yildirim K., Erdal A., Karatay S., Melikoglu M.A., Ugur M., Senel K. Relationship between some acute phase reactants and the Bath Ankylosing Spondylitis Disease Activity Index in patients with ankylosing spondylitis. South Med. J. 2004, 97:350-353.